Skip to main content

Table 3 Base-case results

From: Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

A. Baseline recurrence risk from a Japan-based validation study
Main analysis Without 21-gene assay With 21-gene assay Difference
Proportion receiving adjuvant chemotherapy 46.2% 26.9% −19.2%
10-year recurrence-free survival, % 94.5% 95.0% 0.5%
QALYs    
Adjuvant chemotherapy (immediate) −0.246 −0.144 0.103
Recurrence (long-term) 21.093 21.231 0.139
Total 20.847 21.088 0.241
Costs*    
21-gene assay   ¥350,000 ¥350,000
Acute costs    
Chemotherapy drugs ¥259,298 ¥151,257 -¥108,041
Adverse events ¥78,845 ¥45,993 -¥32,852
Patient time and transportation ¥31,615 ¥18,442 -¥13,173
Monitoring costs until recurrence ¥520,493 ¥524,238 ¥3,744
Costs after recurrence ¥347,446 ¥301,333 -¥46,113
Total ¥1,237,698 ¥1,391,263 ¥153,565
Cost per QALY gained JPY ¥636,752
   USD $6,368
B. Baseline recurrence risk from US- and UK-based validation studies
Alternative analysis Without 21-gene assay With 21-gene assay Difference
Proportion receiving adjuvant chemotherapy 46.2% 26.9% −19.2%
10-year recurrence-free survival, % 89.4% 89.6% 0.3%
QALYs    
Adjuvant chemotherapy (immediate) −0.246 −0.144 0.103
Recurrence (long-term) 19.533 19.590 0.057
Total 19.287 19.447 0.160
Costs*    
21-gene assay   ¥350,000 ¥350,000
Acute costs    
Chemotherapy drugs ¥259,298 ¥151,257 -¥108,041
Adverse events ¥78,845 ¥45,993 -¥32,852
Patient time and transportation ¥31,615 ¥18,442 -¥13,173
Monitoring costs until recurrence ¥478,260 ¥479,798 ¥1,537
Costs after recurrence ¥899,695 ¥882,593 -¥17,102
Total ¥1,747,715 ¥1,928,084 ¥180,369
Cost per QALY gained JPY ¥1,129,442
   USD $11,294
  1. Abbreviations: QALY quality-adjusted–life-year, ¥, JPY Japanese Yen, $, USD United States Dollar.
  2. *Per patient on average. Reported in 2013 currency.